期刊
CURRENT OPINION IN INFECTIOUS DISEASES
卷 25, 期 1, 页码 42-50出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QCO.0b013e32834ef5af
关键词
dual infection; HIV-1; superinfection
资金
- Gilead Sciences
- Merck Sharpe Dohme
- Boehringer Ingelheim
- ViiV Pharmaceuticals
- Janssen (a division of Johnson Johnson)
- Pfizer
- Abbott
Purpose of review This review describes the nature and frequency of HIV-1 superinfection and provides advice regarding counselling of patients in accordance with national guidelines. Recent findings Recent studies have demonstrated conflicting results, from no superinfection to an incidence of over 18%. We discuss the difficulties comparing studies due to population and methodological differences. Summary HIV-infected individuals should be counselled that there is risk of superinfection at all stages of HIV, but this is unlikely to be clinically significant unless transmission of resistance occurs. The risk may be as high as the risk of new incident infection in the presence of on-going exposure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据